#35 – Nir Barzilai, M.D.: How to tame aging
“I think the prevention of aging is really a good place to be. . .and I think life is going to be very different in the next decade with our advances.” —Nir Barzilai
#24 – Tom Dayspring, M.D., FACP, FNLA – Part V of V: Lp(a), inflammation, oxLDL, remnants, and more
“Use the correct terminology with everything.” –Tom Dayspring
Narrative glossary: lipids
A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).
Statins, Lp(a), and upcoming podcast guests
In other words, statins are not addressing the associated risk in patients with an elevated Lp(a), and this population represents about 25% of those with previous CVD or an indication for statins.
#07 – Deep Dive: Lp(a) — what every doctor, and the 10-20% of the population at risk, needs to know
“Elevated Lp(a) may have conferred a survival advantage for most of human history: a better ability to deal with acute trauma, but possibly at the expense of poor handling of chronic damage. In today’s environment, for many people, that’s not an advantage.” —Peter Attia
#03 – Ron Krauss, M.D.: a deep dive into heart disease
“Anybody interested in this field should probably understand the origins.” —Ron Krauss
A big predictor of heart disease risk that most doctors don’t screen for
The most interesting article I read this week was this paper on the NHLBI’s recommendations to reduce Lp(a)-mediated risk of cardiovascular disease.
The straight dope on cholesterol – Part IX
In this post we’ll address the following concept: What should you eat to have the greatest chance of delaying the arrival of cardiovascular disease?
The straight dope on cholesterol – Part VIII
In this post we’ll double-click on a paper covering cholesterol and heart disease risk factors.
The straight dope on cholesterol – Part VII
In this post we’ll address the following concept: Does “HDL” matter after all?